Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

onstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, with no evidence of next day residual sedative effects with either dose. Further, when patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either Intermezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the nigh
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... that it has received approval from the TSX ... outstanding common share purchase warrants ("the Warrants") of ... the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 ... and proteomics technologies, announced today that it is ... system, an innovative multiplex PCR based targeted sequencing ... resolution sequence analysis, that enables accurate detection of ... Relay-PCR™ and Omega-Primer™ technologies. The company will collaborate ...
(Date:4/16/2015)... Mass. (PRWEB) April 16, 2015 ... smart data solutions driven by Semantic Web technology, ... of specialist information and services for the academic ... announced that its joint solution ‘Smart Data Lake ... a finalist for the 2015 Bio-IT ‘Best of ...
(Date:4/16/2015)... 2015  Schulman Associates IRB, Inc., the industry-leading central ... long-term lease on Laboratory Drive in the heart of ... The location will house review board and service staff, ... reviews and customer service to clients. ... in the deal, while Capital Associates Management, LLC represented ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... April 22 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, ... Conference Call, ... Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , How: ... web at the ...
... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading ... China, today,announced that it plans to release first quarter ... market opens., The Company will hold a conference ... to,discuss its fiscal first quarter 2008 results. Listeners may ...
... - Strong Sales Growth Across All Product Lines ... Sales Growth ... IRVINE, Calif., April 22 Edwards Lifesciences,Corporation (NYSE: EW ... disease, today reported net income for the,quarter ended March 31, 2008 ...
Cached Biology Technology:American Oriental Bioengineering to Report First Quarter 2008 Financial Results 2Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 2Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 3Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 4Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 5Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 6Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 7Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 8Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 9Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 10Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 11Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 12Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 13Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 14
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Imagine a cellphone battery that stayed charged for more ... dream battery could be closer to reality thanks to Northwestern ... an electrode for lithium-ion batteries -- rechargeable batteries such as ... batteries to hold a charge up to 10 times greater ...
... -- Feeding older mice a lower glycemic index (GI) ... age-related, sight-threatening retinal lesions, according to a new study ... the Jean Mayer USDA Human Nutrition Research Center on ... researchers studied middle-aged and older mice that consumed either ...
... N.C. In a finding that confirms what many ... younger women who undergo hysterectomies face a nearly two-fold ... published in the December issue of the journal ... track over time the actual hormonal impact of woman ...
Cached Biology News:Better batteries 2Better batteries 3AMD-like lesions delayed in mice fed lower glycemic index diet 2AMD-like lesions delayed in mice fed lower glycemic index diet 3Hysterectomy increases risk for earlier menopause among younger women 2
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Request Info...
Biology Products: